InvestorsHub Logo
Followers 6
Posts 1085
Boards Moderated 0
Alias Born 07/18/2006

Re: None

Wednesday, 09/13/2017 10:01:57 AM

Wednesday, September 13, 2017 10:01:57 AM

Post# of 17403
And another Canaccord analyst said this in March:

"For Canaccord analyst John Newman, these results are clearly “a significant positive” that have him cheering the tolerability of the drug as one that will just keep getting better as time passes. Therefore, staunchly bullish on the biotech firm’s future, the analyst reiterates a Buy rating on AUPH with a price target of $10, which represents a 62% increase from current levels."

https://www.smarteranalyst.com/2017/03/02/canaccord-applauds-aurinia-pharmaceuticals-inc-auph-shares-shatter-roof-66/

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AUPH News